Skip to main content

Wade Iams Archives

Molecular profiles of tissue plus circulating tumor DNA can better guide cancer care

Jan. 22, 2024—Vanderbilt research indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.

Read more


Targeted cancer drug during pregnancy

Aug. 2, 2022—The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.

Read more


Molecular testing across tumor types

Apr. 25, 2022—The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

Read more


Iams honored by National Comprehensive Cancer Network

Jul. 30, 2020—Wade Iams, MD, MSCI, assistant professor of Medicine, is the recipient of a National Comprehensive Cancer Network Foundation Young Investigator Award.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more